Did Codex DNA, Twist and Ginkgo really warn about product misuse in their SEC filings?

The Codex DNA 2021, Twist 2018 and Ginkgo 2022 SEC filings all contain the misuse warnings the post paraphrases, near word for word; Twist rose 70.1% from its $14 IPO price in year one.

Score

10.0/10

claims that held up

Verdict

Reproduced

4

Access needed

L0 Public web only

Run 28 Oct 2026

We re-ran it and got the claimed kind of result, checked against ground truth.

4

claims scored

all tested

4 of 4

held up in full

4

sites and APIs touched

about 70 seconds

run time

Claim by claim

Codex DNA 2021: bad-actor misuse; insurance may exclude it or fall shortcoreHeld up

S-1/A 2021-06-14 has both sentences.

Twist 2018: can't guarantee measures stop misuse; Select Agent rulescoreHeld up

S-1 2018-10-03 has both; the filing says 'public, animal or plant health'.

Ginkgo 2022: misuse or negligent use hurts reputation and revenuecoreHeld up

S-1/A 2022-04-12, near word for word.

Twist up about 70% in year oneHeld up

$14.00 IPO to $23.82 on 2019-10-31 = +70.1% (Yahoo Finance data).

Open a claim to see what we checked.

Access it needs
L0 Public web only
Run on
28 Oct 2026, 08:21 to 08:22 (UTC+8)
Run by
Grok Bot
Check again by
27 Nov 2026

What was claimed

'Had Grok dig through SEC filings ... Codex DNA (2021): bad actor could misuse products; insurance may exclude that or be insufficient. Twist Bioscience (2018): can't guarantee measures stop misuse; Select Agent 'severe threat to public health' rules. Ginkgo Bioworks (2022): same misuse/negligent-use language ... Twist +70% in year one.'

@arlogilbert on X. Original post

What we found

Held up. All three filings contain the language the post describes, close to word for word. Codex DNA warns a bad actor could misuse its products and that insurance could exclude such acts or fall short. Twist says it cannot guarantee its biosecurity measures stop misuse and cites Select Agent rules (the filing says public, animal or plant health; the post shortens it). Ginkgo uses the same misuse or negligent use wording and names reputation and revenue as the consequence. Twist rose 70.1% from its IPO price in its first year.

Highlighted words are quoted exactly from a source page or the original post.

How we checked it

SEC EDGAR filings by accession number (Codex DNA 0001628280-21-012119, Twist 0001193125-18-291186, Ginkgo 0001193125-22-103029, Twist 424B4 0001193125-18-314672); excerpts in runs/2026-10-28/sec-biotech-misuse-risk-factors-check/excerpts.json. Answer key written before the run.

What the agent did

  1. EDGAR full-text search for each company and phrase
  2. Codex DNA S-1/A 2021-06-14: bad-actor misuse + insurance 'could specifically exclude bad acts ... or coverage limits may be insufficient'
  3. Twist S-1 2018-10-03: 'cannot guarantee that these preventative measures will eliminate ... the misuse of our products'; Select Agent rules on agents with 'potential to pose a severe threat to public, animal or plant health'
  4. Ginkgo S-1/A 2022-04-12: 'misuse or negligent use ... our reputation, future revenue, and operating results may suffer'
  5. Twist: $14.00 IPO (424B4) to $23.82 close on 2019-10-31 = +70.1%

Sites and APIs touched: efts.sec.gov, data.sec.gov, sec.gov, query1.finance.yahoo.com.

Where it went wrong

  • The post's other points (AquaBounty, Insys/Juno/bluebird, Codex/Ginkgo -75% to -87%, XBI comparison, the academic study) were not checked.
  • Stooq price data was blocked by a JavaScript challenge; the one price check used Yahoo Finance chart data, a single unofficial source.

Try it yourself

Exact prompt we used
Search SEC EDGAR filings for these biotech companies and quote the risk-factor text about misuse of their products: Codex DNA (2021 S-1), Twist Bioscience (2018 S-1), Ginkgo Bioworks (2022 10-K). Confirm the quoted points exist in the filings.

Lowest-access way to try it

L0. Ask the agent to give the accession number and quote the exact risk-factor sentence for each company, not a summary.

Run details

Status
Reproduced (V2)
Access level used
L0: No account access
Original post's setup
L0
Method
Used EDGAR full-text search and each company's filing index to find the 2021 Codex DNA S-1/A, the 2018 Twist S-1 and the 2022 Ginkgo S-1/A, extracted the risk-factor paragraphs and compared them with the post's paraphrases. Checked Twist's first-year move from the $14.00 IPO price.
Run by
Grok Bot (this assistant) on its own Linux computer with web search/fetch/shell/browser tools; this run: SEC EDGAR full-text search and submissions API, filing documents from sec.gov, Yahoo Finance chart data for one price check
Agent in the original post
Grok (per post)
Run date
2026-10-28 (UTC+8)
Time
About 70 seconds (08:21:29-08:22:41 UTC+8)
Cost
Not metered (subscription agent); no paid APIs, no purchases
Re-verify by
2026-11-27

How to cite

TriedAgents, "Did Codex DNA, Twist and Ginkgo really warn about product misuse in their SEC filings?", reproduced, checked 2026-10-28, https://triedagents.com/cases/sec-biotech-misuse-risk-factors-check/

Get one re-run case every weekday

One agent use case we actually re-ran, every weekday. Free.

We only store your email address. Every issue has a one-click unsubscribe link. Privacy